<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02513303</url>
  </required_header>
  <id_info>
    <org_study_id>VT-304</org_study_id>
    <nct_id>NCT02513303</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes</brief_title>
  <acronym>ACCESS</acronym>
  <official_title>A Phase 3, Randomized, Multicenter, Single-blind, Controlled Study Evaluating Arteriovenous Fistula Outcomes With and Without a Perivascular Sirolimus-Eluting Collagen Implant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vascular Therapies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vascular Therapies, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate efficacy and safety outcomes following use of the&#xD;
      Sirolimus-eluting Collagen Implant (SeCI) in subjects undergoing surgical creation of an AV&#xD;
      fistula for vascular access (index procedure).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate efficacy and safety outcomes following use of the&#xD;
      Sirolimus-eluting Collagen Implant (SeCI) in subjects undergoing surgical creation of an AV&#xD;
      fistula for vascular access (index procedure). Following successful creation of the AV&#xD;
      fistula, the cohort randomized to the treatment group will receive the SeCI; the control&#xD;
      group will not receive an implant. The primary hypothesis is that the proportion of subjects&#xD;
      that meet requirements for fistula suitability for dialysis six months following the index&#xD;
      procedure will be higher in the treatment group in comparison to the control group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">June 2021</completion_date>
  <primary_completion_date type="Actual">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fistula Suitability for Dialysis at 6 Months (FSD6)</measure>
    <time_frame>6 months</time_frame>
    <description>For subjects who are on hemodialysis by day 150, suitability for dialysis will be determined by the ability to use the fistula for dialysis using 2-needles with a mean dialysis machine blood pump speed of ≥300 mL/min for two-thirds of the dialysis sessions during a 30 day suitability ascertainment period that begins 150 days after fistula creation.&#xD;
For subjects who are not on hemodialysis on day of enrollment and who do not initiate hemodialysis by day 150, suitability for dialysis will be determined by a vascular ultrasound performed at the 6 month follow up visit. Suitability for dialysis will be defined as a fistula with an access vein diameter (AVD) of ≥6 mm (internal diameter) and an access blood flow of ≥500 mL/min.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">269</enrollment>
  <condition>Complication of Renal Dialysis</condition>
  <condition>End Stage Renal Disease</condition>
  <condition>End Stage Kidney Disease</condition>
  <condition>ESRD</condition>
  <condition>Chronic Kidney Failure</condition>
  <condition>Complication of Hemodialysis</condition>
  <condition>Vascular Access Complication</condition>
  <condition>Arteriovenous Fistula</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AV fistula surgery Single administration of sirolimus-eluting Collagen implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>AV fistula surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>A single dose of sirolimus delivered locally</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Rapamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AV Fistula Surgery</intervention_name>
    <description>AV Fistula Surgery</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirolimus-eluting Collagen Implant (SeCI)</intervention_name>
    <description>SeCI placed at and around the site of the anastomosis of an AV fistula, immediately following completion of a successful AV fistula surgery.</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Rapamycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Currently on hemodialysis for ≤12 months or expected to initiate hemodialysis within&#xD;
             approximately 6 months of the creation of the AV fistula.&#xD;
&#xD;
          -  Vascular anatomy suitable for creation of the AV fistula, determined by pre procedure&#xD;
             duplex ultrasound&#xD;
&#xD;
          -  Successful creation of a single stage radiocephalic or brachiocephalic end to side&#xD;
             fistula&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior AV access created on the limb where the fistula surgery is planned&#xD;
&#xD;
          -  ST-elevation MI or cerebrovascular accident within 30 days of the index procedure&#xD;
&#xD;
          -  Known hypersensitivity to the following: sirolimus, beef or bovine collagen&#xD;
&#xD;
          -  Hypotension with systolic blood pressures &lt;100 mm Hg at the time of screening&#xD;
&#xD;
          -  Known or suspected active infection at the time of the AV fistula surgery&#xD;
&#xD;
          -  Known to be HIV positive&#xD;
&#xD;
          -  Prisoner, mentally incompetent, and/or alcohol or drug abuser&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sriram Iyer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Vascular Therapies, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nephrology Consultants, LLC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKDHC Medical Research Service</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Institute of Medical Research</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Clinical Research Center</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 29, 2015</study_first_submitted>
  <study_first_submitted_qc>July 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2015</study_first_posted>
  <disposition_first_submitted>July 11, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>July 15, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 19, 2021</disposition_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dialysis</keyword>
  <keyword>End Stage Renal Disease</keyword>
  <keyword>End Stage Kidney Disease</keyword>
  <keyword>ESRD</keyword>
  <keyword>Chronic Kidney Failure</keyword>
  <keyword>Chronic Renal Failure</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Vascular Access</keyword>
  <keyword>Arteriovenous Fistula</keyword>
  <keyword>AV Fistula</keyword>
  <keyword>AVF</keyword>
  <keyword>Nephrology</keyword>
  <keyword>Vascular Surgery</keyword>
  <keyword>Dialysis Access</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Arteriovenous Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

